RxDoctor Payments Data

Katherine Herold, MD

Family Medicine · Louisville, KYNPI 1568506749

Payments from drug & device makers

$10,180in general payments, 2019–2025

Across 528 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$998
  • Pfizer$866
  • Vanda Pharmaceuticals Inc.$760
  • Otsuka America Pharmaceutical, Inc.$520
  • Novo Nordisk$515
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,159100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,180 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$23,638
Medicare patients
129
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol42$46,843
MounjaroTirzepatide28$37,011
OzempicSemaglutide24$28,171
JanuviaSitagliptin Phosphate15$20,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,755
Nurtec OdtRimegepant Sulfate15$14,342
TrulicityDulaglutide13$12,543
Repatha SureclickEvolocumab15$10,238
NexletolBempedoic Acid12$7,756
LinzessLinaclotide11$6,324
MyrbetriqMirabegron11$4,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,558
Levothyroxine Sodium80$1,093
Rosuvastatin Calcium105$908
Omeprazole80$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$210$49,55541 claims
AstraZenecaFarxiga$998$46,84342 claims
Novo NordiskOzempic$515$28,17124 claims
MerckJanuvia$180$20,73815 claims
GSKTrelegy Ellipta$475$19,75516 claims
PfizerNurtec Odt$866$14,34215 claims
Esperion Therapeutics, Inc.Nexletol$231$7,75612 claims
AbbVieLinzess$1,617$6,32411 claims
Astellas Pharma US IncMyrbetriq$296$4,79511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →